-
-
-
-
-
-
-
Ipsen receives new FDA PDUFA date for investigational palovarotene for the treatment of people with FOP
-
-
-
-
-
-
-
Telesta Therapeutics and Ipsen Announce Exclusive License Agreement for MCNA1 for the Treatment of Non-Muscle Invasive Bladder Cancer in Major Ex-United States Territories
-
-
15,571 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

